Xenon Q2 net loss $84.7M; azetukalner Phase 3 X-TOLE2 enrollment complete, topline early 2026

Xenon Pharmaceuticals Inc.

2025-Q2 EPS reported -$1.90 revenue$7,500,000

Net loss $84.7M vs $57.9M Q2 2024; R&D expenses rose to $75.0M from $49.7M on azetukalner trials.
Phase 3 X-TOLE2 (focal seizures) patient recruitment complete; topline data expected early 2026.
Phase 1 studies underway for XEN1120 (Kv7) and XEN1701 (Nav1.7) pain candidates.
Darren Cline appointed Chief Commercial Officer to lead commercial build for azetukalner launch.
Cash $624.8M as of June 30, 2025; funding expected into 2027.

item 2.02item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.